<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<!--The publisher of this article does not allow downloading of the full text in XML form.-->
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">Can J Psychiatry</journal-id>
<journal-id journal-id-type="iso-abbrev">Can J Psychiatry</journal-id>
<journal-id journal-id-type="publisher-id">CPA</journal-id>
<journal-id journal-id-type="hwp">spcpa</journal-id>
<journal-title-group>
<journal-title>Canadian Journal of Psychiatry. Revue Canadienne de Psychiatrie</journal-title>
</journal-title-group>
<issn pub-type="ppub">0706-7437</issn>
<issn pub-type="epub">1497-0015</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage CA: Los Angeles, CA</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">29742910</article-id>
<article-id pub-id-type="pmc">6364139</article-id>
<article-id pub-id-type="doi">10.1177/0706743718773728</article-id>
<article-id pub-id-type="publisher-id">10.1177_0706743718773728</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>In Review Series Articles</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>An Overview of Animal Models Related to Schizophrenia</article-title>
<trans-title-group xml:lang="fr">
<trans-title>Un aperçu des modèles animaux liés à la schizophrénie</trans-title>
</trans-title-group>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Winship</surname>
<given-names>Ian R.</given-names>
</name>
<degrees>PhD</degrees>
<xref ref-type="aff" rid="aff1-0706743718773728">1</xref>
<xref ref-type="corresp" rid="corresp2-0706743718773728"></xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Dursun</surname>
<given-names>Serdar M.</given-names>
</name>
<degrees>MD, PhD</degrees>
<xref ref-type="aff" rid="aff2-0706743718773728">2</xref>
<xref ref-type="aff" rid="aff3-0706743718773728">3</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Baker</surname>
<given-names>Glen B.</given-names>
</name>
<degrees>PhD</degrees>
<xref ref-type="aff" rid="aff2-0706743718773728">2</xref>
<xref ref-type="aff" rid="aff3-0706743718773728">3</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Balista</surname>
<given-names>Priscila A.</given-names>
</name>
<degrees>PhD</degrees>
<xref ref-type="aff" rid="aff4-0706743718773728">4</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Kandratavicius</surname>
<given-names>Ludmyla</given-names>
</name>
<degrees>PhD</degrees>
<xref ref-type="aff" rid="aff5-0706743718773728">5</xref>
</contrib>
<contrib contrib-type="author">
<contrib-id authenticated="false" contrib-id-type="orcid">http://orcid.org/0000-0002-7637-2498</contrib-id>
<name>
<surname>Maia-de-Oliveira</surname>
<given-names>Joao Paulo</given-names>
</name>
<degrees>MD, PhD</degrees>
<xref ref-type="aff" rid="aff3-0706743718773728">3</xref>
<xref ref-type="aff" rid="aff6-0706743718773728">6</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Hallak</surname>
<given-names>Jaime</given-names>
</name>
<degrees>MD, PhD</degrees>
<xref ref-type="aff" rid="aff3-0706743718773728">3</xref>
<xref ref-type="aff" rid="aff5-0706743718773728">5</xref>
<xref ref-type="aff" rid="aff7-0706743718773728">7</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Howland</surname>
<given-names>John G.</given-names>
</name>
<degrees>PhD</degrees>
<xref ref-type="aff" rid="aff8-0706743718773728">8</xref>
<xref ref-type="corresp" rid="corresp1-0706743718773728"></xref>
</contrib>
</contrib-group>
<aff id="aff1-0706743718773728">
<label>1</label>Neuroscience and Mental Health Institute, University of Alberta, Edmonton, Alberta</aff>
<aff id="aff2-0706743718773728">
<label>2</label>Department of Psychiatry, Neurochemical Research Unit and Bebensee Schizophrenia Research Unit, Neuroscience and Mental Health Institute, University of Alberta, Edmonton, Alberta</aff>
<aff id="aff3-0706743718773728">
<label>3</label>National Institute of Science and Technology—Translational Science, Brazil</aff>
<aff id="aff4-0706743718773728">
<label>4</label>Department of Pharmacy, Centro Universitario das Faculdades Metropolitanas Unidas, São Paulo, Brazil</aff>
<aff id="aff5-0706743718773728">
<label>5</label>Department of Neuroscience and Behavior, Faculty of Medicine of Ribeirao Preto, University of São Paulo, Ribeirao Preto, Brazil</aff>
<aff id="aff6-0706743718773728">
<label>6</label>Department of Clinical Medicine, Rio Grande do Norte Federal University, Natal, Brazil</aff>
<aff id="aff7-0706743718773728">
<label>7</label>Department of Psychiatry (NRU), University of Alberta, Edmonton, Alberta</aff>
<aff id="aff8-0706743718773728">
<label>8</label>Department of Physiology, University of Saskatchewan, Saskatoon, Saskatchewan</aff>
<author-notes>
<corresp id="corresp1-0706743718773728">John Howland, PhD, Department of Physiology, University of Saskatchewan, Rm GD30.7, 107 Wiggins Rd, Saskatoon, SK, Canada S7N 5E5. Email: <email>john.howland@usask.ca</email></corresp>
<corresp id="corresp2-0706743718773728">Ian Winship, PhD, Neurochemical Research Unit, 12-127 Clinical Sciences Building, Department of Psychiatry, University of Alberta, Edmonton, AB, Canada T6G 2R3. Email: <email>iwinship@ualberta.ca</email></corresp>
<fn fn-type="COI-statement" id="fn1-0706743718773728">
<p><bold>Declaration of Conflicting Interests:</bold> The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.</p>
</fn>
</author-notes>
<pub-date pub-type="epub">
<day>09</day>
<month>5</month>
<year>2018</year>
</pub-date>
<pub-date pub-type="ppub">
<month>1</month>
<year>2019</year>
</pub-date>
<volume>64</volume>
<issue>1</issue>
<fpage>5</fpage>
<lpage>17</lpage>
<permissions>
<copyright-statement>© The Author(s) 2018</copyright-statement>
<copyright-year>2018</copyright-year>
<copyright-holder content-type="sage">Canadian Psychiatric Association</copyright-holder>
</permissions>
<abstract>
<p>Schizophrenia is a heterogeneous psychiatric disorder that is poorly treated with current therapies. In this brief review, we provide an update regarding the use of animal models to study schizophrenia in an attempt to understand its aetiology and develop novel therapeutic strategies. Tremendous progress has been made developing and validating rodent models that replicate the aetiologies, brain pathologies, and behavioural abnormalities associated with schizophrenia in humans. Here, models are grouped into 3 categories—developmental, drug induced, and genetic—to reflect the heterogeneous risk factors associated with schizophrenia. Each of these models is associated with varied but overlapping pathophysiology, endophenotypes, behavioural abnormalities, and cognitive impairments. Studying schizophrenia using multiple models will permit an understanding of the core features of the disease, thereby facilitating preclinical research aimed at the development and validation of better pharmacotherapies to alter the progression of schizophrenia or alleviate its debilitating symptoms.</p>
</abstract>
<trans-abstract xml:lang="fr">
<p>La schizophrénie est un trouble psychiatrique hétérogène qui n’est pas bien traité par les thérapies actuelles. Dans cette brève revue, nous offrons une mise à jour concernant l’utilisation de modèles animaux pour étudier la schizophrénie en vue d’en comprendre l’étiologie et d’élaborer de nouvelles stratégies thérapeutiques. Des progrès formidables ont été réalisés dans le développement et la validation de modèles rongeurs qui reproduisent les étiologies, les pathologies cérébrales et les anomalies comportementales associées à la schizophrénie chez les humains. Ici, les modèles sont groupés en 3 catégories: développementale, induite par des médicaments, et génétique pour refléter les facteurs de risque hétérogènes associés à la schizophrénie. Chacun de ces modèles est associé à une pathophysiologie, des endophénotypes, des anomalies comportementales, et des déficiences cognitives variés mais se chevauchant. Étudier la schizophrénie à l’aide de modèles multiples nous permettra de comprendre les caractéristiques essentielles de la maladie, facilitant ainsi la recherche préclinique qui vise le développement et la validation de meilleures pharmacothérapies afin de modifier la progression de la schizophrénie ou d’en atténuer les symptômes invalidants.</p>
</trans-abstract>
<kwd-group>
<kwd>animal models</kwd>
<kwd>schizophrenia</kwd>
<kwd>dopamine</kwd>
<kwd>glutamate</kwd>
<kwd>5-hydroxytryptamine (5-HT</kwd>
<kwd>serotonin)</kwd>
</kwd-group>
</article-meta>
</front>
</article>
</pmc-articleset>